These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27481951)

  • 1. Advancing New Antibacterial Drug Development for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia.
    Toerner JG; Rubin D
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S37-8. PubMed ID: 27481951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Donnelly H; Alemayehu D; Botgros R; Comic-Savic S; Eisenstein B; Lorenz B; Merchant K; Pelfrene E; Reith C; Santiago J; Tiernan R; Wunderink R; Tenaerts P; Knirsch C
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S39-45. PubMed ID: 27481952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs.
    Kinamon T; Waack U; Needles M; Rubin D; Collyar D; Doernberg SB; Evans SR; Hamasaki T; Holland TL; Howard-Anderson J; Chambers H; Fowler VG; Nambiar S; Kim P; Boucher HW; Gopinath R
    Clin Infect Dis; 2024 Jul; 79(1):60-69. PubMed ID: 38527855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumonia.
    Talbot GH
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S144-9. PubMed ID: 20597665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Trials.
    Bart SM; Rubin D; Kim P; Farley JJ; Nambiar S
    Clin Infect Dis; 2021 Aug; 73(3):e602-e608. PubMed ID: 33173946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
    Jones RN
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S81-7. PubMed ID: 20597676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
    ; ; ; ; Spellberg B; Talbot G
    Clin Infect Dis; 2010 Aug; 51 Suppl 1(Suppl 1):S150-70. PubMed ID: 20597666
    [No Abstract]   [Full Text] [Related]  

  • 9. End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: food and drug administration perspective.
    Laessig KA
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S117-9. PubMed ID: 20597659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.
    Weiss E; Zahar JR; Alder J; Asehnoune K; Bassetti M; Bonten MJM; Chastre J; De Waele J; Dimopoulos G; Eggimann P; Engelhardt M; Ewig S; Kollef M; Lipman J; Luna C; Martin-Loeches I; Pagani L; Palmer LB; Papazian L; Poulakou G; Prokocimer P; Rello J; Rex JH; Shorr AF; Talbot GH; Thamlikitkul V; Torres A; Wunderink RG; Timsit JF
    Clin Infect Dis; 2019 Nov; 69(11):1912-1918. PubMed ID: 30722013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues in the design of clinical trials for antibacterial drugs for hospital-acquired pneumonia and ventilator‐associated pneumonia. Proceedings of a workshop co-sponsored by the US Food and Drug Administration, Infectious Diseases Society of America, American College of Chest Physicians, American Thoracic Society, and Society of Critical Care Medicine. March 31-April 1 2009.
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S1-170. PubMed ID: 21058464
    [No Abstract]   [Full Text] [Related]  

  • 12. The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.
    François B; Chastre J; Eggiman P; Laterre PF; Torres A; Sanchez M; Esser MT; Bishop B; Bonten M; Goosens H; Jafri HS
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S46-51. PubMed ID: 27481953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Workshop on clinical trials of antibacterial agents for hospital-acquired pneumonia and ventilator-associated pneumonia.
    Bartlett JG; Barie PS; Niederman MS; Wunderink RG
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S1-3. PubMed ID: 20597654
    [No Abstract]   [Full Text] [Related]  

  • 14. Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children: A Prospective Natural History and Case-Control Study.
    Ericson JE; McGuire J; Michaels MG; Schwarz A; Frenck R; Deville JG; Agarwal S; Bressler AM; Gao J; Spears T; Benjamin DK; Smith PB; Bradley JS;
    Pediatr Infect Dis J; 2020 Aug; 39(8):658-664. PubMed ID: 32150005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Leister-Tebbe H; Hill C; Geres H; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW;
    Clin Infect Dis; 2024 Feb; 78(2):259-268. PubMed ID: 37740559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.
    Barriere SL
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S4-9. PubMed ID: 20597670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Public-Private Collaborations Are Driving Solutions to the Antibacterial Drug Development Crisis.
    Madre L; Tenaerts P
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S25-6. PubMed ID: 27481948
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.
    Stergiopoulos S; Calvert SB; Brown CA; Awatin J; Tenaerts P; Holland TL; DiMasi JA; Getz KA
    Clin Infect Dis; 2018 Jan; 66(1):72-80. PubMed ID: 29020279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Talbot GH; Das A; Cush S; Dane A; Wible M; Echols R; Torres A; Cammarata S; Rex JH; Powers JH; Fleming T; Loutit J; Hoffmann S;
    J Infect Dis; 2019 Apr; 219(10):1536-1544. PubMed ID: 30649434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
    Barriere SL
    Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.